Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report.
Testosterone therapy
cardiometabolic risk factors
obesity
type 2 diabetes
“late-onset” hypogonadism
Journal
SAGE open medical case reports
ISSN: 2050-313X
Titre abrégé: SAGE Open Med Case Rep
Pays: England
ID NLM: 101638686
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
03
2018
accepted:
14
12
2018
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
6
2
2019
Statut:
epublish
Résumé
For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile dysfunction. He had type 2 diabetes, was overweight, and had hypertension and dyslipidemia. The blood test revealed testosterone deficiency. Under testosterone therapy, the patient lost 10 kg; cardiometabolic parameters returned to normal and lower urinary tract symptoms disappeared; complete remission of diabetes was recorded. Overweight and obese patients with type 2 diabetes should be tested for hypogonadism and testosterone therapy, if indicated, be considered. These patients can considerably benefit from testosterone therapy in terms of sustainable weight loss and a clinically significant reduction of cardiometabolic risk factors including complete remission of diabetes.
Identifiants
pubmed: 30719309
doi: 10.1177/2050313X18823454
pii: 10.1177_2050313X18823454
pmc: PMC6349975
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2050313X18823454Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.H. has received partial funding for a registry study and travel grants from Bayer AG; K.H. has received travel grants from Bayer AG; F.S. is a full-time employee of Bayer AG.
Références
Obes Rev. 2000 Oct;1(2):57-9
pubmed: 12119987
Health Qual Life Outcomes. 2003 May 01;1:15
pubmed: 12747807
Int J Clin Pract. 2006 Jul;60(7):762-9
pubmed: 16846397
J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59
pubmed: 20525905
J Clin Endocrinol Metab. 2011 Sep;96(9):2898-903
pubmed: 21778224
Obes Surg. 2012 Dec;22(12):1835-42
pubmed: 22923309
JAMA Surg. 2014 Mar;149(3):275-87
pubmed: 24352617
Int J Endocrinol. 2014;2014:527470
pubmed: 24688542
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):313-22
pubmed: 25105998
Diabetes Care. 2014 Dec;37(12):3188-95
pubmed: 25231895
Diabetologia. 2015 Jul;58(7):1448-53
pubmed: 25924987
Int J Obes (Lond). 2016 Jan;40(1):162-70
pubmed: 26219417
Diabetes Care. 2016 Jan;39(1):82-91
pubmed: 26622051
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
BMJ. 2017 Sep 13;358:j4030
pubmed: 28903916
Endocrinol Diabetes Metab Case Rep. 2017 Sep 04;2017:null
pubmed: 28924480
J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):465-481
pubmed: 29542875